Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

A Critical Look at the Efficacy and Costs of Biologic Therapy for Chronic Rhinosinusitis with Nasal Polyposis

(2020) W. Colby Brown et al.   CURRENT ALLERGY AND ASTHMA REPORTS

Understanding the Patient Experience of Severe, Recurrent, Bilateral Nasal Polyps: A Qualitative Interview Study in the United States and Germany

(2020) Rebecca Hall et al.   VALUE IN HEALTH

EUFOREA Consensus on Biologics for CRS w NP with or without asthma

(2019) W J Fokkens et al.   ALLERGY

Biological treatments for severe asthma: A major advance in asthma care

(2019) William W. Busse   ALLERGOLOGY INTERNATIONAL

Is It Time for a Patient-Centered Quality Measure of Asthma Control?

(2019) Elizabeth Herman et al.   Journal of Allergy and Clinical Immunology-In Practice

Dupilumab improves health‐related quality of life in patients with chronic rhinosinusitis with nasal polyposis

(2019) Claus Bachert et al.   ALLERGY

Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis

(2019) Tsurumaki et al.   Medicina-Lithuania

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

(2019) Claus Bachert et al.   LANCET

Biologics for the treatment of chronic rhinosinusitis with nasal polyps - state of the art

(2019) Lei Ren et al.   World Allergy Organization Journal

Asthma

(2018) Alberto Papi et al.   LANCET

Increasing confidence in the therapeutic relevance of eosinophils in severe asthma

(2018) Marc Humbert   Lancet Respiratory Medicine

Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies

(2018) J Mark FitzGerald et al.   Lancet Respiratory Medicine

Baseline Patient Factor Impact on the Clinical Efficacy of Benralizumab for Severe Asthma

(2018) Eugene R. Bleecker et al.   EUROPEAN RESPIRATORY JOURNAL

EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists

(2018) W.J. Fokkens et al.   RHINOLOGY

Biologic Agents for the Treatment of Chronic Rhinosinusitis With Nasal Polyps

(2018) Alison G. Kartush et al.   American Journal of Rhinology & Allergy

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

(2018) William W Busse et al.   Lancet Respiratory Medicine

Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

(2017) Parameswaran Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chronic rhinosinusitis severity is associated with need for asthma-related systemic corticosteroids

(2017) K.M. Phillips et al.   RHINOLOGY

Asthma quality of life and control after sinus surgery in patients with chronic rhinosinusitis

(2016) R. J. Schlosser et al.   ALLERGY

Real-life study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre

(2016) J. van der Veen et al.   ALLERGY

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

(2016) Eugene R Bleecker et al.   LANCET

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

(2016) J Mark FitzGerald et al.   LANCET

Reductions in eosinophil biomarkers by benralizumab in patients with asthma

(2016) Tuyet-Hang Pham et al.   RESPIRATORY MEDICINE

Chronic rhinosinusitis management beyond intranasal steroids and saline solution irrigations

(2015) Newton Li et al.   ALLERGY AND ASTHMA PROCEEDINGS

Airway Inflammation in Chronic Rhinosinusitis with Nasal Polyps and Asthma: The United Airways Concept Further Supported

(2015) Kåre Håkansson et al.   PLoS One

Comparison of intranasal fluticasone spray, budesonide atomizer, and budesonide respules in patients with chronic rhinosinusitis with polyposis after endoscopic sinus surgery

(2015) Paul D. Neubauer et al.   International Forum of Allergy & Rhinology

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

(2014) Elisabeth H. Bel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

(2014) Hector G. Ortega et al.   NEW ENGLAND JOURNAL OF MEDICINE

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

(2013) K. F. Chung et al.   EUROPEAN RESPIRATORY JOURNAL

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia

(2013) Michel Laviolette et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Aeroallergen Sensitization Influences Quality of Life and Comorbidities in Patients with Nasal Polyposis

(2012) Ignacio Dávila et al.   American Journal of Rhinology & Allergy

Global asthma prevalence in adults: findings from the cross-sectional world health survey

(2012) Teresa To et al.   BMC PUBLIC HEALTH

Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor α antibody, in a phase I study of subjects with mild asthma

(2010) William W. Busse et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

(2010) Roland Kolbeck et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Psychometric validity of the 22-item Sinonasal Outcome Test

(2009) C. Hopkins et al.   CLINICAL OTOLARYNGOLOGY